Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort
Parkinsonism & Related Disorders, 06/26/2012
Wahlqvist ML et al. – Incident Parkinson's disease (PD) risk in Type 2 diabetes (T2DM) increases 2.2–fold. Sulfonylureas further increase risk by 57%, which is avoided by combination with metformin.